Science of Health Department, School of Medicine, University "Magna Graecia" of Catanzaro, Catanzaro, Italy.
Curr Top Behav Neurosci. 2022;55:145-167. doi: 10.1007/7854_2020_216.
According to the definition of epileptogenesis, "disease modification" refers to every clinically relevant therapeutic outcome which does not necessarily prevent epilepsy onset but significantly improves the disease course by reducing seizure burden and/or decreases concomitant comorbidities. In this light, understanding comorbidities development, their characteristics, and the neurobiological causes represents a major issue both in clinical and preclinical research. This chapter is summarizing and critically evaluating the preclinical improvements over time in the study of epilepsy comorbidities reconsidering some of them according to the newer results. Furthermore, we highlight limitations and possibilities both in the methods used and in the mechanisms considered. The latter have been analysed also as potential therapeutic targets for therapy development. Finally, differences and similarities between induced epilepsy models and genetic models have been underlined in the chapter.
根据癫痫发生的定义，“疾病修饰”是指每一种具有临床相关性的治疗结果，它不一定能预防癫痫发作，但通过减少发作负担和/或减少伴随的合并症，显著改善疾病进程。从这个角度来看，了解合并症的发展、其特征和神经生物学原因，无论是在临床还是在临床前研究中，都是一个主要问题。本章总结和批判性地评估了随着时间的推移，在癫痫合并症研究方面的临床前进展，根据最新的结果重新考虑了其中的一些进展。此外，我们还强调了在使用的方法和考虑的机制方面存在的局限性和可能性。这些机制也被分析为治疗开发的潜在治疗靶点。最后，在该章节中强调了诱导性癫痫模型和遗传模型之间的差异和相似之处。
